Test Index
1571094173876_5da4ed08e27e0a0004ce3b9e_logo
1584055867459_5e6ab9a4acd991000434a556_logo
American Heart Association logo
$20 million research initiative supports health equity in high blood pressure prevention
(NewMediaWire) - April 19, 2021 - DALLAS - The American Heart Association, the world’s leading voluntary organization dedicated to a world of longer, healthier lives, is investing $20 million to study ways to prevent high blood pressure, particularly in underrepresented populations. Applications are now being accepted for coordinated submission of three to five research centers and a coordinating center that will be funded through this fast-track initiative. Letters of intent are required and due by Friday, April 23, 2021. The Health Equity Research Network (HERN) on the Prevention of Hypertension is part of the multi-pronged approach of the American Heart Association’s unprecedented pledge to aggressively address social determinants while working to support and improve the equitable health of all communities. High blood pressure is one of the leading risk factors of heart disease and stroke and is also a health equity issue. Significant racial and ethnic disparities in both prevalence of hypertension and its management have been well documented. Uncontrolled hypertension is particularly acute in communities of color. As such, this research initiative provides a mechanism to advance the science of prevention of hypertension with a focus on health equity. According to the American Heart Association Heart Disease and Stroke Statistics – 2021 Update: Nearly half of all U.S. adults (47.3%, 121.5 million people age 20 or older) have high blood pressure. The prevalence of hypertension in Black people in the U.S. is among the highest in the world - 56.6% among males and 55.3% among females. Black adults are more likely (33.0%) to have been told on two or more occasions that they had hypertension than American Indian/Alaska Native adults (26.4%), white adults (23.5%), Hispanic or Latino adults (22.9%) or Asian adults (19.5%). The lifetime risk for high blood pressure is 86.1% for Black males, 85.7% for Black females, 83.8% for white males and 69.3% for white females. Scientific research teams interested in applying for the new grants can get more information here. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1. ### For Media Inquiries: Cathy Lewis, cathy.lewis@heart.org; (214) 706-1324 For Public Inquiries: 1-800-AHA-USA1 (242-8721) heart.org and stroke.org
Tauriga Sciences Inc. Introduces its Newest Product Line: The Tauri-Gum Summertime Collection
This Product Line is Comprised of Embroidered: Hiking Backpack (with accessories), Folding Beach Chair, and Insulated Can CoolerNEW YORK, NY - (NewMediaWire) - April 19, 2021 - Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry, Evergreen Mint), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today introduced its newest product line: The Tauri-Gum™ Summertime Collection (“Summer Collection”). This product line is beautifully embroidered and is comprised of: 1) Hiking Backpack (with accessories), 2) Folding Beach Chair, and 3) Insulated Can Cooler. The Summer Collection will be available on the Company’s E-Commerce website (www.taurigum.com), starting in May 2021.The Company developed its “Summer Collection” product line to promote outdoor activities, during this upcoming summer. Fun! Fitness! Sun! Safety! The Embroidered Hiking Backpack will come with several notable accessories: one Tauri-Gum™ Rainbow Pack, two Embroidered Face Masks, and two Embroidered Can Coolers. The MSRP for the Hiking Backpack (with accessories): $149.99The Embroidered Folding Beach Chair will come with two Embroidered Can Coolers. The MSRP is set at $64.99The Embroidered Insulated Can Coolers will be sold for: MSRP of $8.99 EachThe Embroidered Hiking BackpackABOUT TAURIGA SCIENCES INC.Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.comComplementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.DISCLAIMER -- Forward-Looking StatementsThis press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” ...
Neovasc Comments on EuroIntervention Article
VANCOUVER and MINNEAPOLIS - (NewMediaWire) - April 19, 2021 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the journal EuroIntervention has published an article entitled, “Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at Cardiopulmonary Exercise Test in Patients with Refractory Angina.” The article, authored by Carlo Zivelonghi, M.D., Antwerp Cardiovascular Center, Antwerp, Belgium, describes objective improvements in effort tolerance and oxygen kinetics as assessed by cardiopulmonary exercise testing (CPET) in patients suffering from refractory angina treated with Neovasc Reducer™ (“Reducer”) implantation.In this multicenter prospective study, 37 patients with chronic refractory angina undergoing Reducer implantation were evaluated with CPET at baseline (before treatment) and at six-month follow-up after implantation of the device. The main endpoints of the analysis were improvements in VO2 max and in VO2 at anaerobic threshold (AT), measures which reflect cardiorespiratory fitness and endurance capacity in exercise performance. The results showed that Reducer treatment significantly improved cardiopulmonary parameters, reflected by improvement in VO2 max (+0.97 ml/kg/min [+11.3%], 12.2±3.6 ml/kg/min vs 13.2±3.7, p=0.026), and workload (+12.9 [+34%]; 68±28 W vs 81±49W, p=0.05). Angina severity reflected by the Canadian Cardiovascular Society (CCS) grading improved from a mean of 3.2±0.5 to 1.6±0.8, (p<0.01). Improvements in all Seattle Angina Questionnaire variables were also shown.“For the first time, we were able to demonstrate objective improvement in exercise capacity and oxygen kinetics during exercise,” said Dr. Maayan Konigstein, M.D., Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Israel. “VO2 max is an indicator of cardiorespiratory fitness, and the improved cardiopulmonary exercise capacity following treatment with Reducer is suggestive of improvement in myocardial ischemia and in exercise tolerance in these patients.”Fred Colen, President & Chief Executive Officer of Neovasc, added, “We congratulate the authors for their innovative work. We believe demonstrating objective evidence of improvement in oxygenated blood flow to the heart muscle and related objective outcomes, such as exercise ability and associated improved key cardiopulmonary parameters, provides further support for the improvement in overall clinical outcomes, as already indicated for patients receiving the Reducer. It is remarkable to see statistically significant improvements in these important cardiopulmonary parameters in such a small patient population.”Improvement in angina symptoms was observed in 32 patients (86.5%), with a mean improvement in CCS grade at follow up of 1.6±0.8. Only very limited differences in anti-anginal medications were recorded, with a mean of 1.9±1.1 drugs per patient at baseline vs 1.8±1.1 at follow-up (p=0.77). Prof. Stefan Verheye, M.D., PhD, Antwerp Cardiovascular Center Middelheim, Antwerp, Belgium, said, “It is reassuring to see the consistent improvements in chest pain in patients treated with the Reducer. The outcomes reported in this study build upon the literature supporting Reducer as an attractive option for patients suffering from refractory angina that are not candidates for traditional revascularization procedures.”About Reducer The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow within the myocardium of the heart and increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is ...
NBA Star and Television Personality John Salley Joins One World Pharma's Board of Advisors
Las Vegas, NV - (NewMediaWire) - April 19, 2021 - One World Pharma Inc. (OTC: OWPC), (“OWP” or the “Company”), a U.S. based, fully licensed, pure-play hemp and cannabis ingredient producer in Colombia, is pleased to announce that NBA star, television personality and businessman John Salley has joined the Company’s growing Board of Advisors.As the #11 selection in the 1986 NBA Draft, Mr. Salley played 15 years in the NBA and was the first player to win four championships with three different teams. During the 1980s, Salley was a member of the iconic Detroit Pistons “Bad Boys” squad alongside NBA All-Time great and One World Pharma CEO Isiah Thomas. Salley would later win championships with the Chicago Bulls and Los Angeles Lakers. He has continued his success in film and television and is considered a highly influential voice in sports and popular culture. Mr. Salley is also an entrepreneur in the cannabis industry, launching his own brand Deuces22 and taking an ownership stake in the cannabis testing company Greenspace Labs. He also is an advisory member of Budtrader.Mr. Salley joins a growing Board of Advisors that is chaired by Minyon Moore, who is widely considered one of the nation’s top strategic thinkers with extensive experience in political and corporate affairs as well as public policy. Ms. Moore was named one of the 100 Most Powerful Women in Washington by Washington Magazine, and has been inducted into the American Association of Political Consultants (AAPC) Hall of Fame.“John was not just my teammate on one of the most successful championship teams in NBA history, he is a creative executive with an incredible history of winning in sports, entertainment, and more,” said Isiah Thomas, CEO, of One World Pharma. “I fully expect John to contribute immediately, to provide both advice and introductions, and to be an integral part of our effort to be an international supplier of the finest cannabis ingredients in the marketplace.”“It is my distinct pleasure to once again join my teammate and dear friend Isiah in the pursuit of excellence in an industry where I am deeply passionate,” stated John Salley. “I’ve watched with interest since Isiah first came on board with One World Pharma and noted with admiration how he has steered the Company to the broader opportunities within the cannabis industry and done so with a model grounded in socially conscious business practices.”About One World PharmaFormed in 2017, One World Pharma Inc. (“OWP”) is a fully licensed global supplier of high-quality hemp-derived ingredients for use in the manufacturing of Consumer Packaged Goods (CPGs) and Over-the-Counter (OTC) products. OWP offers a reliable and sustainable supply chain for chemical formulators, food & beverage producers as well as beauty product manufacturers worldwide. The company maintains corporate offices in Las Vegas, NV and Bogota Colombia and a facility in Popayan, Colombia. One World Pharma Investor Relations & Financial MediaKurt Divich, CEOIntegrity Media Inc.team@integritymedia.comToll Free: (888) 216-3595www.IntegrityMedia.comInformation about Forward-Looking StatementsThis press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the failure to close the remaining funding installments with ISIAH International, the Company's need for additional funding, the demand for the Company's products, governmental ...
Medical Marijuana, Inc. Reports $46.9M in Revenue and Increased Margins in 2020 Year-End Financial and Operational Results Filing
SAN DIEGO, CA - (NewMediaWire) - April 19, 2021 - Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain,announced today financial results for the quarter and year ending Dec. 31, 2020, and provided an overview of recent operational highlights."While the entire world felt the impact of 2020, I could not be more proud of how our team remained flexible and executed on our mission of bringing the highest-quality, cannabinoid-based products to global markets," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "We were able to finish 2020 on a strong note and go into 2021 with significant positive momentum. It has been encouraging to witness an increased demand for wellness products and sweeping victories on every pro-cannabis legislation proposal in the US. In the first quarter of 2021 alone, new states such as New York, New Jersey, Virginia and New Mexico have entered the cannabis industry and several federal cannabis bills are likely to pass in Congress soon. As an industry pioneer and leader, we remain not only optimistic about our results, but about how we are positioned to capitalize on the future of our industry.”Year-End 2020 Financial Highlights● Generated $46.9 million in net revenue in 2020;● Gross Margins increased from 76% in 2019, to 80% in 2020● GAAP Sales & Marketing expense decreased as a percentage of sales from 55% in 2019 to 48% in 2020;● Cash position at the end of 2020 was $5.7 million;Year-End 2020 Operational Highlights● Completed clinical study using its Real Scientific Hemp Oil-X™ cannabidiol (CBD) oil and published results inthe EC Neurology (ECNE), an internationally peer-reviewed journal that publishes articles related to worldwide research in neuroscience;● SubsidiaryKannaway®participated in the 2020 Validcare clinical study on CBD liver toxicity;● Reached a two-year milestone for long-term stability testing on its flagship THC-free CBD oil product Real Scientific Hemp Oil-X™ (RSHO-X™) in a stability study conducted in strict compliance with FDA/ICH guidelines (Q1A-R2);● Expanded its production and warehouse facility, further vertically integrating the Company’s supply chain, enabling broader product R&D and internal manufacturing;● Dr. Titus was honored as a Bronze 2020 CEO World Award winner for Top CEO of the Year - The Visionary, a Gold Stevie® Award winner for Executive of the Year - Food & Beverage and a 2020 Golden Bridge Business and Innovation Awards Gold Award - Lifetime Achievement Award winner;● Pharmaceutical investment company Neuropathix, formerly known as Kannalife, Inc., completed its phase 1 study funded by a grant (1R41DA044898-01) from the National Institutes of Health's (NIH) National Institute on Drug Abuse (NIDA);● Subsidiary Kannaway® launched in the U.S. cannabinol (CBN) market with the release of two new CBN isolate products in the US and entered the European cannabigerol (CBG) market with the release of its Kannaway® Premium CBG;● Subsidiary Kannaway® was named the Most Popular Cannabidiol MLM Company in HealthMJ's 2020 list and one of the Top 100 MLM Companies of 2020 by Business for Home;● Subsidiary Kannaway® expanded into Russia, Kazakhstan and Kyrgyzstan;● Blake Schroeder honored with a 2020 CEO World Awards Silver Award for Top CEO of the Year - The Maverick, Silver Stevie® Award for Maverick of the Year, Business Intelligence Group’s 2020 BIG Awards for Business Top CEO of the Year Award, and Top CEO of the Year Award from the International Association of Top Professionals;● Subsidiary Kannaway® launched the first-ever CBD fitness program, Evolve;● Subsidiary Kannaway® honored with Gold Stevie® Award for Achievement in Web Design, Bronze Stevie® Award for Company of the Year – Health Products & Services – Small and Bronze Stevie® Award for Achievement in International Expansion;● Subsidiary HempMeds® Mexico opened a new ...
Sports Venues of Florida (OTCMKTS: BTHR) Releases Management Report for the Week Ended April 17, 2021
United States Patent and Trademark Office Has Agreed to Publish GGToor Trademark Thomasville, GA - (NewMediaWire) - April 19, 2021 - Sports Venues of Florida, Inc. (OTCMKTS: BTHR) (“Sports Venues of Florida”, “BTHR”, or the “Company”), an emerging leader in the youth sports, family sports entertainment, and eSports markets, announces the United States Patent and Trademark Office has agreed to publish GGToor Trademark, (serial number 90267166), in the Office’s Official Gazette. “I could not be more pleased that the US Patent and Trademark Office after a rather exhausting nine months, has cleared our mark to be published. The security and value this will bring to our Company is absolutely astronomical. What is Nike without their Swoosh? Amazon without their Smile? Now GGToor has their GG. We finally OWN A BRAND. Shareholders and investors should be popping open the Champagne with this news, ” said John V Whitman Jr., Chairman/CEO/President.Any third-party who has legal grounds to oppose our application has a period of thirty days from the publication date to file a notice of opposition. We do not anticipate any issues with opposition and expect the process to proceed. If no opposition is filed, after about eleven weeks we should receive a Notice of Allowance from the Trademark Office and the Company will file a Statement of Use showing how our mark is being used. The GGToor Trademark covers the following specific goods and services;IC 009. US 021 023 026 036 038. G & S: Downloadable video game software; Downloadable computer software, namely, game engine software for video game development and operation; Virtual reality headsets adapted for use in playing video games; computer hardware, namely, Apparatus for transmitting and reproduction of sound; Downloadable computer game software via a global computer network and wireless devices; Pre-recorded CDs, videotapes, laser disks and DVDs featuring animated cartoons; Pre-recorded CDs, videotapes, laser disks and DVDs featuring gamingIC 018. US 001 002 003 022 041. G & S: Wallets and pocket wallets; backpacks; sports bags; bum bags and handbagsIC 025. US 022 039. G & S: Clothing, namely, shirts, sweatshirts, hooded sweatshirts, jumpers, socks, bandannas, scarves, head scarves, jackets, footwear, head wear, and t-shirtsIC 028. US 022 023 038 050. G & S: Gaming headsets adapted for use in playing video games; Game controllers in the nature of keyboards for computer games; Playing cards and card games; Playing card game accessories, namely, playing card cases, playing card holders, mats for use in connection with playing card games, playing card shuffling devices and dice; dice games; Action figure toys; Soft sculpture toys; kits for making toys, namely, toy model kit cars; mini Playing pieces in the nature of miniature action figures and toy model vehicles for use with table top hobby battle games in the nature of battle, war and skirmish games, and fantasy games; Tables for table footballIC 035. US 100 101 102. G & S: Promotional sponsorship of professional video games teams, namely, promoting the goods and services of others by arranging for businesses to affiliate their goods and services with the goods and services of third parties by means of sponsorship relationships; talent agency services for professional video game playersIC 042. US 100 101. G & S: Computer programming of video games; Video game programming development servicesLast week not only brought the Company great news concerning the GGToor Trademark, but it also brought the Company so much more.Management is working as hard as possible to keep up and build value to our platform for our sponsors to promote their brand and take advantage of what GGToor has to offer. Our discord growth this month has been amazing and far exceeded expectations; only three short weeks after hitting the 3,000-member mark toward the end of March, we have already added over 1,000 more new members, surpassing the 4,000-member milestone this weekend!The Community was extremely excited for this weekend's Pokemon:TCG Online event, which ...